Microbiome Sequencing Market Research, 2031
The global microbiome sequencing market size was valued at $859.4 million in 2021, and is projected to reach $3,417.09 million by 2031, growing at a CAGR of 14.8% from 2022 to 2031. Microbiome sequencing is defined as a research technology that includes the study of microbes and their roles in the maintenance of healthcare as well as the prevalence of diseases. The gut contains the majority of the human body's microorganisms, which have a variety of functions in host biology and dysbiosis. In addition, unbalanced microbiomes can lead to inflammation, the production of harmful compounds, the disruption of the immune system, and the development of diseases in both the immediate and remote environment. The goal of human microbiome profiling analysis is the study of microbial communities found in and on the human body.
Historical Overview
The market was analyzed qualitatively and quantitatively from 2021-2031. The microbiome sequencing market grew at a CAGR of around 14.8% during 2021-2031. Most of the growth during this period was derived from the Asia-Pacific owing to the owing to factors such as increase in investments in microbiome research, awareness regarding microbiome sequencing and applications related to it in the region.
Market Dynamics
Growth & innovations in the pharmaceutical industry for the launching of microbiome sequencing services owing to massive pool of health-conscious consumers, creates an opportunity for the microbiome sequencing market. Rise in launch of various sequencing services offering facilities, rise in investments for microbiome research by various key players across the globe is set to affect the market growth positively. The growth of the microbiome sequencing market is expected to be driven by emerging markets, due to availability of improved healthcare infrastructure, increase in unmet healthcare needs, rise in prevalence of chronic diseases in adults, and surge in demand for next generation sequencing technology. Furthermore, the healthcare industry in emerging economies is developing at a significant rate, owing to rise in demand for enhanced healthcare services, significant investments by government to improve healthcare infrastructure, and development of the medical tourism industry in emerging countries.
The microbiome sequencing market growth is driven by the rise in research and development institutes in the biological field growing studies over genomics and increasing prevalence of chronic diseases. The rising demand from next-generation sequencing expansion of microbiome sequencing services, its application and reduction in the cost of sequencing are the factors driving the market growth. The growing awareness and benefits of microbiome sequencing for cancer treatment are fueling the market. For instance, according to article published in BMC 2021, stated that, microbiome sequencing was used for understanding the composition of tissue microbiomes and useful in prediction of prognosis of colorectal cancer using 16S rRNA amplicon sequencing. Further, rise in use of human microbiome for drug development and utilization of sequencing techniques for development of personalized medicines is anticipated to drive the growth of microbiome sequencing market. The rise in the incidence of chronic diseases is significantly influencing the microbiome sequencing market forecast.
Various organizations along with government are counselling people regarding the applications of microbiome sequencing. The demand for microbiome sequencing techniques is not only limited to developed countries but is also being witnessed in the developing countries, such as China, Brazil, and India, which fuel the growth of the market. Factors such as rise in adoption of microbiome sequencing and increase in awareness toward use of sequencing further drive the growth of the market. Moreover, increase in promotional activities by manufacturers, growth in awareness about microbiome, and rise in demand of next generation sequencing among the general population are expected to fuel their adoption in the near future.
However, factor such as the lack of skilled persons in the operating system restrains the growth of the microbiome sequencing market. In addition, stringent rules, and regulations by the government for microbiome sequencing also might hinder the growth of the market. In contrast, increase in advancements for developing effective sequencing services and the need of next-generation sequencing technology provide lucrative opportunities to the market players.
The outbreak of COVID-19 has disrupted workflows in the healthcare sector around the world. The disease has forced a number of industries to shut their doors temporarily, including several sub-domains of health care. However, the COVID-19 pandemic had a positive impact on the market growth, owing to the increase in microbiome research for the understanding relationship between the virus and human health. In addition, sequencing techniques can be used to study virus phylogeny and alert from further diseases, thus also boosting microbiome sequencing market opportunity.
Segmental Overview
The microbiome sequencing market is segmented into technique, research, end user, and region. By technique, the market is categorized into shotgun sequencing, RNA sequencing, targeted gene sequencing, whole-genome sequencing, and others. On the basis of research, the market is segregated into outsourced and internal. On the basis of end user, the market is categorized into pharmaceutical and biotechnology companies and academic centers and research centers. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
By Technique:
Depending on technique, the market is categorized into shotgun sequencing, RNA sequencing, targeted gene sequencing, whole-genome sequencing, and others. The RNA sequencing segment accounted for the largest microbiome sequencing market share owing to the offering of 16S, ITS2 rRNA gene sequencing services by the majority of the players. In addition, the shotgun sequencing segment exhibited the highest growth during the forecast period as it provides whole coverage of microbiome taxonomy including virus which is highly preferred and has short turnaround time
By Research:
Depending on research, the market is bifurcated into outsourced and internal. The outsourcing segment accounted for the largest microbiome sequencing market share in 2021 and is also expected to remain dominant during the forecast period, owing to rise in outsourcing of sequencing to reduce costs and hassles while streamlining the end-to-end process.
By End User:
On the basis of end user, the market is segmented into pharmaceutical & biopharmaceutical companies and academic centers & research centers. The academic centers & research centers segment accounted for the largest microbiome sequencing market size in 2021 and is also expected to remain dominant during the forecast period owing rise in microbiome research activities carried and convenient protocol, shorter operation time, and precision in results.
By Region:
The microbiome sequencing market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America accounted for the largest microbiome sequencing market size, in terms of revenue, owing to increase in awareness towards microbiome sequencing and rise in government initiatives promoting research activities for development of new advanced sequencing techniques drives the market growth. Upsurge in healthcare expenditure in the emerging economies is anticipated to offer lucrative opportunities for the market expansion. However, Asia-Pacific is anticipated to witness notable growth, owing to increase in investments for development of microbiome sequencing techniques and increase in use of microbiomes in genomics and proteomics drives the growth of market during the forecast period.
Presence of several major players, such as Microbiome Insights, Charles River Laboratories International, Inc., Zymo Research Corporation, and advancement in sequencing technology for development of effective sequencing services for diagnosis and treatment in the region drive the growth of the market. Furthermore, presence of well-established healthcare infrastructure, and rise in adoption rate of sequencing services for disease detection are expected to drive the market growth. Furthermore, various service approvals and contract agreements as key strategies have been adopted by the key players in this region, which further boost the growth of the market. For instance, Zymo Research announced its support of seven new pilot projects at the University of California, Irvine (UCI) where it is expected to be one of the sponsors of the 2019 UCI Microbiome Initiative. In addition, various key players are collaborating for microbiome research and to understand relationship between microbes and disease at faster pace. For instance, Oxford Nanopore and Novogene will collaborate to expand the types of application available using nanopore sequencing, to take advantage of nanopore’s rich data and ability to sequence short to ultra-long fragments of DNA/RNA.
Asia-Pacific is expected to grow at the highest rate during the forecast period. The market growth in this region is attributable to presence of key players in the region. Moreover, rise in adoption of various sequencing services for detection of disease drive the growth of the market. Several microbiome companies are receiving funding in Japan for research into the microbiome and to examine the connection between bacteria and disease states, which supports the market's expansion. For instance, according to news of bitBiome 2020, stated that, bitBiome, Inc., received approx. $10 million to launch a large-scale study on patient stool and saliva samples for more than 20 diseases, including cancer, intestinal diseases, autoimmune diseases, and neuropsychiatric disorders in Japan. Asia-Pacific offers profitable opportunities for key players operating in the microbiome sequencing market, thereby registering the fastest growth rate during the forecast period, owing to the growing infrastructure of industries, rising microbiome research, as well as well-established presence of domestic companies in the region. In addition, rise in contract manufacturing organizations within the region provides great opportunity for new entrants in this region.
Competition Analysis
Competitive analysis and profiles of the major players in the microbiome sequencing market, such as Baseclear BV, Microbiome Insights, Clinical Microbiomics, CosmosID, Novogene Co., Ltd., Charles River Laboratories International, Inc., OraSure Technologies (Diversigen), Zymo Research Corporation, Resphera Biosciences, LLC, and Molecular Research LP. are provided in this report. Major players have adopted product launch, acquisition, contract and partnership agreement, as key developmental strategies to improve the services of the microbiome sequencing market.
Some Examples Of Contract In The Market
In June 2022, Microbiome Insights, Inc., a global leader for end-to-end microbiome sequencing industry and comprehensive bioinformatic analysis, announced that it was awarded a $881,000 contract from Health Canada to develop a testing platform to accurately identify and characterize micro-organisms found in microbial biotechnology products, and predict their interactions that could mask or enhance adverse effects to determine risks to human and environmental health.
Partnership In The Market
In February 2020, A CosmosID Inc. and Biomeostasis, SAS announced strategic partnership focused on standardization of pre-clinical microbiome R&D.
Service Launch In The Market
In October 2019, Microbiome Insights launched new shallow shotgun sequencing service.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the microbiome sequencing market analysis from 2021 to 2031 to identify the prevailing microbiome sequencing industry opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the microbiome sequencing market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global microbiome sequencing market trends, key players, market segments, application areas, and market growth strategies.
Microbiome Sequencing Market Report Highlights
| Aspects | Details |
 Market Size By 2031 | USD 3.4 billion |
 Growth Rate | CAGR of 14.8% |
 Forecast period | 2021 - 2031 |
 Report Pages | 235 |
 By Technique |
|
 By Research |
|
 By End user |
|
 By Region |
|
 Key Market Players | Novogene Co., Ltd. , Molecular Research LP, OraSure Technologies (Diversigen), Clinical Microbiomics, Resphera Biosciences, LLC, CosmosID, Charles River Laboratories International, Inc., Zymo Research Corporation, Baseclear BV, Microbiome Insights |
Analyst Review
This section provides various opinions of top-level CXOs in the global microbiome sequencing market. According to the insights of CXOs, increase in demand for microbiome research and rise in investments for microbiome research globally is expected to offer profitable opportunities for the expansion of the market. In addition, favorable government policies and schemes for microbiome sequencing have piqued the interest of several companies to develop advanced sequencing techniques.
CXOs further added that increase in use of sequencing techniques for diagnosis of infectious, gastrointestinal diseases, various chronic diseases such as cancer and cardiovascular disease in developing regions has largely contributed to the market revenue in 2021 and is expected to maintain this trend throughout the forecast period. Furthermore, increased demand for next-generation sequencing technologies in many countries and awareness regarding use of microbiome sequencing to understand the link between the microbiome and disease, contribute significantly to the revenue generation. Moreover, use of sequencing techniques for cancer diagnosis is anticipated to boost the growth of market.
Furthermore, North America is expected to witness highest growth, in terms of revenue, owing to increase in awareness toward microbiome sequencing and rise in government initiatives promoting research activities for development of new advanced sequencing techniques. Upsurge in healthcare expenditure in the emerging economies is anticipated to offer lucrative opportunities for the market expansion. However, Asia-Pacific is anticipated to witness notable growth, owing to rise in investments for development of microbiome sequencing techniques and increase in use of microbiomes in genomics & proteomics.
Utilization of microbiome sequencing in early disease diagnosis and utilization of this technology in the development of personalized medicines for various diseases are the upcoming trends of market.
RNA Sequencing is the leading technique of microbiome sequencing market.
North America is the largest regional market for microbiome sequencing market.
Major Key players that operate in the global microbiome sequencing market are Baseclear BV, Charles River Laboratories International, Inc., Clinical Microbiomics, CosmosID, Microbiome Insights, Molecular Research LP, Novogene Co., Ltd., OraSure Technologies (Diversigen), Resphera Biosciences Llc and Zymo Research Corporation.
The microbiome sequencing market valued for $859.42 million in 2021 and is estimated to reach $3,417.09 million by 2031, exhibiting a CAGR of 14.8% from 2022 to 2031.
2021 is the base year of the microbiome sequencing market.
2022 to 2031 is the forecast year of the microbiome sequencing market.
Loading Table Of Content...
